Candida species live on the skin and mucous membranes of most healthy people without causing problems. When immunity is weakened by HIV, chemotherapy, transplant drugs, or broad-spectrum antibiotics, these fungi can shift from commensals to dangerous pathogens. Candida albicans remains the most common culprit, causing oral thrush and bloodstream infections that can be fatal in immunocompromised patients.[3] Meanwhile, multidrug-resistant Candida auris has been designated an "urgent threat" by the U.S. Centers for Disease Control and Prevention. Researchers are now asking whether monolaurin — a compound derived from coconut oil and present in human breast milk — has useful antifungal activity. The answer, so far, is promising but incomplete.

This article examines the laboratory, animal, and limited human evidence on monolaurin and Candida. For broader context, see What Is Monolaurin?.

How Monolaurin Attacks Candida: The Membrane Disruption Mechanism

Monolaurin's antifungal action appears to follow the same strategy as its antibacterial and antiviral effects: physical disruption of lipid membranes. Rather than targeting a specific enzyme or metabolic pathway, monolaurin inserts into lipid bilayers and destabilizes their structure. For details, see how monolaurin works.

Several lines of evidence support membrane disruption as the primary mechanism against Candida rather than interference with fungal virulence factors. In a 2016 in vitro study, monolaurin showed no significant effect on C. albicans proteinase or phospholipase enzyme activities, and no significant downregulation of the virulence genes SAP-1 or PLB-1.[3] If monolaurin were disarming the fungus by inhibiting virulence machinery, those markers would likely shift. Their absence points toward a less specific, laboratory-observed mechanism: physical compromise of the cell envelope.

This same mechanism makes monolaurin active against enveloped viruses (all four tested were inhibited) while leaving non-enveloped viruses completely unaffected[8] — a pattern consistent with a compound whose target is the lipid membrane itself, not any pathogen-specific protein. The parallel logic applies to fungi: Candida cell membranes contain the lipid structures that monolaurin can insert into and disrupt. For more on the antibacterial side of this mechanism, including scanning electron microscopy showing membrane damage in Staphylococcus aureus, see our article on monolaurin and bacteria.

Candida albicans Biofilms: The Best-Studied Target

Most Candida infections in humans don't involve free-floating (planktonic) cells. Instead, the fungus builds biofilms — structured communities encased in a protective extracellular matrix that adheres to mucosal surfaces, dentures, and medical devices. Biofilms account for approximately 65% of all human microbial infections, and biofilm-associated fungal infections cause over one million deaths annually worldwide.[2] Biofilm-resident Candida cells are far more resistant to antifungal drugs than their planktonic counterparts, which is why researchers have focused specifically on whether monolaurin can penetrate and disrupt these structures.

Killing Planktonic Cells vs. Disrupting Biofilms

It is important to distinguish between two separate capabilities: killing individual Candida cells in suspension and disrupting established biofilm communities. The concentrations required are very different.

Against planktonic C. albicans, monolaurin's minimum inhibitory concentration (MIC) ranges from 62.5 to 125 µM, and its minimum fungicidal concentration (MFC) — the dose needed to actually kill, not just inhibit — is 125 to 250 µM. These values were consistent across multiple strains, including a fluconazole-resistant isolate.[3]

Biofilms, however, require substantially higher doses. In the 2016 in vitro study, monolaurin at 1,250 µM and 2,500 µM (10× and 20× the planktonic MIC) produced statistically significant reductions in C. albicans biofilm fungal load as measured by colony-forming units.[3] Fluorescence microscopy of treated biofilms showed sparser, less dense fungal accumulation compared to untreated controls.[3]

Monolaurin was active against a fluconazole-resistant C. albicans isolate at a concentration more than three times lower than fluconazole itself — a finding that underscores its potential relevance as drug resistance narrows the existing antifungal arsenal.[3]

The Mouse Study: From Petri Dish to Living Host

The most significant advance came in 2018, when researchers conducted what they described as the first-ever in vivo demonstration that monolaurin can reduce C. albicans biofilm burden in a living host.[2] Using immunosuppressed mice infected with a bioluminescent strain of C. albicans — engineered to glow in proportion to its population size, enabling real-time tracking — they applied monolaurin topically to the oral cavity twice daily.

By day four, monolaurin had reduced the fungal burden to a level statistically indistinguishable from nystatin, the gold-standard topical antifungal used as a positive control.[2] When the mice were euthanized and their tongues analyzed ex vivo, the monolaurin-treated animals had significantly fewer colony-forming units per gram of tongue tissue than vehicle controls.[2] No signs of toxicity were observed: treated mice showed normal weight gain, normal development, and no pathological changes in vital organs.[2]

There are important caveats. Only 15 mice were used in the entire study — five per group — which limits statistical power.[2] The monolaurin concentration used (12.5 mmol/L) was 100 times the upper bound of its planktonic MIC.[2] And a slight rebound in fungal signal at day five hinted that the dosing regimen may need optimization.[2] Still, this was a genuine proof-of-concept: monolaurin reduced Candida biofilms in a living animal, not just in a test tube.

Anti-Inflammatory Dual Action

One of the more intriguing findings from the biofilm research is that monolaurin may simultaneously reduce the inflammatory damage that Candida infections trigger in host tissue. In a co-culture model pairing C. albicans with human oral fibroblasts, monolaurin at 125 µM significantly downregulated the pro-inflammatory cytokine IL-1α, and at 62.5 µM it significantly downregulated IL-1β.[3]

However, the immune modulation pattern was inconsistent: IL-1α was affected at the higher dose but not the lower one, while IL-1β showed the opposite pattern.[3] Whether this non-dose-dependent behavior reflects genuine biological complexity or is an artifact of the in vitro system remains unclear. The same study also noted that at antifungal concentrations (62.5–125 µM), approximately 20% of fibroblast cells were affected, meaning there is a partial cytotoxicity trade-off at therapeutic doses.[3]

Candida auris: A Multidrug-Resistant Threat

Candida auris is a very different challenge from C. albicans. First identified in 2009, it is frequently resistant to all three major classes of antifungal drugs and has caused deadly outbreaks in hospitals worldwide. New agents that work against C. auris are urgently needed.

In a 2025 study, both monolaurin (GML) and its sulfur-modified analog NB2 were tested against two clinical isolates of C. auris. GML killed both isolates at a minimum bactericidal concentration (MBC) of 100 µg/mL, while NB2 achieved the same result at 50 µg/mL — half the dose.[1]

This is strictly in vitro data, and only two isolates were tested. But two additional findings make it noteworthy. First, when 10⁸ C. auris cells were incorporated into agar containing twice the MBC of either NB2 or GML for up to 48 hours, no resistant colonies emerged.[1] This is consistent with monolaurin's multi-target membrane disruption mechanism: because it attacks the physical structure of the cell envelope rather than a single molecular target, it is much harder for the fungus to evolve resistance through a single mutation.

Second, neither GML nor NB2 killed Lactobacillus crispatus — both compounds actually stimulated its growth.[1] This selectivity matters, and we address it in detail below.

Why NB2 Matters

NB2 is not monolaurin. It is a synthetic analog in which the oxy-ester bond of monolaurin has been replaced with a dual-sulfur dithionate linkage. This structural change makes NB2 invisible to bacterial lipases — enzymes produced by pathogens like S. aureus that cleave monolaurin into glycerol and lauric acid, the latter being at least 200 times less antimicrobially active than intact monolaurin.[1] A control compound with only one sulfur substitution (NB1) was still hydrolyzed by bacterial lipase, confirming that the dual-sulfur structure is specifically required for lipase resistance.[1]

NB2 was not toxic to human vaginal epithelial cells at concentrations up to 100 µg/mL, with greater than 95% viability after six hours of exposure.[1] In rabbit skin challenge experiments using a bacterial dose roughly 1,000 times higher than typical colonization levels, NB2-treated animals showed no visible toxicity compared to controls.[1]

NB2 is pre-clinical. No human trials have been conducted with it. But its improved potency against C. auris and resistance to enzymatic degradation make it a compound worth watching.

Lactobacillus-Sparing Selectivity: Why It Matters

One of monolaurin's most distinctive properties — and one that separates it from most conventional antimicrobials — is its selectivity toward pathogens over beneficial bacteria. In both the NB2 study and earlier clinical work, monolaurin and its analogs consistently spare or even stimulate Lactobacillus crispatus, a keystone species in the healthy vaginal microbiome.[1]

This selectivity has significant implications for Candida applications. Vaginal candidiasis (yeast infection) is one of the most common fungal infections in women, and conventional antifungal treatments do not always discriminate between pathogenic fungi and protective bacteria. Disrupting the vaginal Lactobacillus population can create conditions favorable for reinfection and for bacterial vaginosis. A compound that kills Candida while preserving or stimulating Lactobacillus would, in theory, break this cycle.

The Lactobacillus connection runs even deeper. Lactobacillus reuteri naturally produces reutericyclin, a structural analog of monolaurin, which has been shown to independently inhibit HIV-1 infection by 40–50% in vitro.[8] A 2015 study confirmed that topical monolaurin did not disrupt the normal Lactobacillus vaginal microbiota in rhesus macaques.[8] The picture that emerges is of a compound that works with the existing microbial ecosystem rather than against it — a marked contrast to broad-spectrum antibiotics and antifungals. For the broader story on monolaurin's relationship with beneficial bacteria, see our article on monolaurin and bacteria.

The Human Evidence: One Small Trial and a Failed Follow-Up

The clinical evidence for monolaurin against Candida in humans can be stated simply: it is extremely thin.

A 2010 randomized controlled trial by Strandberg and colleagues found that monolaurin reduced vaginal Candida colonization while sparing Lactobacillus.[1] This is the finding most often cited by proponents of monolaurin for yeast infections, and the selectivity result is real and consistent with the in vitro and animal data.

However, the same research group conducted a follow-up Phase II trial for bacterial vaginosis (a related but distinct condition), and that trial failed its primary endpoint. Monolaurin reduced vaginal Candida in the BV trial as well, but it did not significantly reduce Gardnerella vaginalis, the key BV pathogen.[1] This matters because it shows that monolaurin's selectivity — killing some organisms while sparing others — cuts both ways: it may spare beneficial bacteria, but it may also spare certain pathogens.

No large-scale antifungal trials of monolaurin have been published. The mouse oral candidiasis study[2] provides animal-level proof of concept, but the gap between 5 mice and clinical medicine is vast. For broader context on monolaurin's safety profile and the dosing uncertainties that make clinical translation challenging, see our article on monolaurin safety and dosage.

Formulation Research: Solving the Delivery Problem

One of monolaurin's practical challenges is that it has limited water solubility, which makes it difficult to deliver effectively to mucosal surfaces where Candida infections occur.[5] Several research groups have tackled this through novel formulation approaches. It is important to understand what these studies are: they are engineering work aimed at improving delivery, not clinical evidence that monolaurin treats oral thrush or other Candida infections.

Nanocapsules

A 2016 study developed GML-loaded nanocapsules — tiny polymer shells approximately 193 nm in diameter — and tested them against C. albicans biofilms in vitro. The nanocapsule formulation cut the planktonic MIC in half (15.5 µg/mL vs. 31.25 µg/mL for free GML) and achieved a 94% reduction in biofilm biomass at 48 hours.[4] Notably, free (unencapsulated) GML did not significantly reduce biofilm biomass in this same assay,[4] suggesting that the nanocapsule delivery system dramatically enhances monolaurin's ability to penetrate the biofilm matrix — a finding that may help explain why the concentrations needed for biofilm disruption are so much higher than planktonic MICs when using free monolaurin.[3]

Gel-Like Microemulsions

A 2022 study incorporated monolaurin into gel-like microemulsions designed for the oral cavity. The formulations released most of their monolaurin within two hours and decreased C. albicans survival within three hours, though there was a lag time between drug release and antifungal effect — consistent with the time needed for monolaurin to permeate through the fungal cell wall.[5] The formulations showed acceptable stability after temperature cycling tests.[5]

Nanofibers

A 2021 study fabricated gelatin nanofibers encapsulating GML microemulsions. These nanofibers demonstrated fast dissolution and effective antimicrobial activity against E. coli and S. aureus.[6] However, this study was primarily designed for edible food packaging applications and tested bacterial, not fungal, targets.[6] Its relevance to Candida is indirect — it demonstrates that monolaurin can be successfully incorporated into nanofiber delivery systems that maintain antimicrobial activity.

Taken together, the formulation research suggests that monolaurin's anti-biofilm potential may be substantially limited by its delivery in free form, and that encapsulation technologies could unlock greater efficacy. But none of these formulations have been tested in animals or humans for Candida infections.

Species Specificity: What We Know and What We Don't

It would be inaccurate to say "monolaurin kills Candida" as a blanket statement. Here is what the data actually covers:

How the Antifungal Evidence Compares to the Antibacterial and Antiviral Data

Monolaurin's antibacterial evidence includes synergy studies with β-lactam antibiotics against MRSA, where combinations restored antibiotic potency by up to 256-fold in vitro.[7] Its antiviral evidence includes in vitro activity against enveloped viruses including HIV-1, mumps, yellow fever, and Zika, along with animal studies in rhesus macaques.[8] For full coverage, see our articles on monolaurin and bacteria and monolaurin and viruses.

The antifungal evidence sits somewhere in between. It has the advantage of an in vivo mouse study that the antibacterial synergy work lacks (which remains entirely in vitro[7]), but it lacks the large-animal studies that exist for the antiviral application (the macaque SIV trials[8]). Across all three domains — antibacterial, antiviral, and antifungal — the controlled human evidence is thin, and the fundamental mechanism (membrane disruption) appears to be the same.

The Bottom Line: What We Know and What We Don't

The evidence supports several specific claims about monolaurin and Candida:

What the evidence does not support is any clinical recommendation. We do not have large-scale human trial data for monolaurin as an antifungal. The single RCT showing vaginal Candida reduction was small, and the follow-up trial for a related condition failed its primary endpoint.[1] The formulation studies are pre-clinical engineering work, not efficacy studies.[4, 5, 6] The mouse data, while encouraging, involved only 15 animals.[2]

Monolaurin's anti-Candida profile — membrane disruption, biofilm activity, microbiome selectivity, lack of resistance emergence — is distinctive. But laboratory properties are not the same as proven clinical therapies. For now, monolaurin is a biologically interesting compound with a clear mechanism and a large clinical evidence gap.